BAM
TAK icon

Bruderman Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Bruderman Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-393
Closed -$8K – 511
2019
Q1 		$8K Buy
+393
New +$7.91K ﹤0.01% 462

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bruderman Asset Management's TAK Position: Q2 2019 in Review

Bruderman Asset Management sold out of Takeda Pharmaceutical (TAK) in Q2 2019, closing a stake of 393 shares — an estimated $8K sold.

Bruderman Asset Management first reported a position in TAK in Q1 2019 and held it in 1 quarter. The position peaked at $8K in Q1 2019. 347 funds tracked by Wall St. Rank hold TAK as of Q2 2019.

  • Bruderman Asset Management reported no remaining Takeda Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 393 Takeda Pharmaceutical shares in Q2 2019, an estimated $8K.
  • Bruderman Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • Bruderman Asset Management's Takeda Pharmaceutical position peaked at $8K in Q1 2019.
  • 347 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.